We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Elanco Animal Health Inc (ELAN) NPV

Sell:$13.36 Buy:$13.37 Change: $0.04 (0.30%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$13.36
Buy:$13.37
Change: $0.04 (0.30%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$13.36
Buy:$13.37
Change: $0.04 (0.30%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.

Contact details

Address:
2500 Innovation Way N
GREENFIELD
46140-9163
United States
Telephone:
+ ()
Website:
https://www.elanco.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ELAN
ISIN:
US28414H1032
Market cap:
$6.64 billion
Shares in issue:
494.35 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Jeffrey Simmons
    President, Chief Executive Officer, Director
  • Todd Young
    Chief Financial Officer, Executive Vice President
  • Shiv O'Neill
    Executive Vice President, General Counsel, Company Secretary
  • David Kinard
    Executive Vice President, Human Resources, Corporate Communications and Administration
  • Timothy Bettington
    Executive Vice President - Corporate Strategy and Market Development
  • Ramiro Cabral
    Executive Vice President , President of Elanco International
  • Ellen de Brabander
    Executive Vice President - Innovation and Regulatory Affairs
  • Grace Mcardle
    Executive Vice President - Manufacturing and Quality
  • Rajeev Modi
    Executive Vice President - U.S. Pet Health and Global Digital Transformation
  • Jose Manuel Simas
    Executive Vice President - U.S. Farm Animal Business

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.